DBV Technologies S.A Price to Free Cash Flow Ratio 2015-2021 | DBVT

Historical price to free cash flow ratio values for DBV Technologies S.A (DBVT) since 2015. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
DBV Technologies S.A Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2021-10-15 5.30 0.00
2021-06-30 5.46 $-0.61 0.00
2021-03-31 5.33 $-0.33 0.00
2020-12-31 2.62 0 0.00
2020-03-31 3.92 $-0.49 0.00
2019-12-31 10.70 0 0.00
2019-06-30 8.22 0 0.00
2018-12-31 6.42 0 0.00
2018-06-30 19.29 0 0.00
2017-12-31 24.60 0 0.00
2017-06-30 35.71 0 0.00
2016-12-31 35.13 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.583B $0.011B
DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00